Cell News and Research

RSS

Study of combination therapy versus monotherapy for pulmonary arterial hypertension

Gilead Sciences, Inc., in collaboration with GlaxoSmithKline (GSK), today announced plans for an international, event-driven (morbidity and mortality) clinical trial to study combination therapy versus monotherapy in a first-line treatment setting for pulmonary arterial hypertension (PAH).

2 Nov 2009

Juvaris BioTherapeutics commences enrollment in its JVRS-100 influenza vaccine adjuvant study

Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines for infectious diseases, today announced that it has begun enrolling patients in a Phase 2 clinical trial of its lead compound, JVRS-100, as an adjuvant for seasonal influenza vaccines in the elderly population.

2 Nov 2009

VEGF from the retinal pigment epithelium to the choriocapillaris leads to degeneration of the CC, study finds

Scientists at Schepens Eye Research Institute have found that when the eye is missing a diffusible form of vascular endothelial growth factor (VEGF), i.e. one that when secreted can reach other cells at a distance, the retina shows defects similar to "dry" macular degeneration, also called geographic atrophy (GA).

2 Nov 2009

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new pre-clinical research findings from its transthyretin (TTR)-mediated amyloidosis (ATTR) program at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (“The Liver Meeting”).

2 Nov 2009

NOXXON Pharma commences human dosing in Spiegelmer NOX-A12 clinical trial

NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, announced today the successful initial dosing of healthy volunteers in a first-in-human clinical trial with Spiegelmer® NOX-A12. NOX-A12 is NOXXON’s second drug candidate entering the clinical stage of development within only five months.

2 Nov 2009

BMY and ZGen present Phase 1B results for PEG-Interferon lambda in HCV patients

Bristol-Myers Squibb Company and ZymoGenetics, Inc. today presented final results from a Phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-naïve hepatitis C virus (HCV) patients.

2 Nov 2009

InteRNA Technologies and Dana-Farber Cancer Institute team up for cancer research

InteRNA Technologies B.V. and the Dana-Farber Cancer Institute (Boston, USA) have entered into a research agreement to develop microRNA (miRNA)-based therapeutics for cancer.

2 Nov 2009

Vitrolife takes over sales and marketing management of fertility media in UK and Ireland

Vitrolife (STO:VITR) is taking over management of marketing and sales of fertility media in UK and Ireland. “The acquisition is in line with Vitrolife’s strategy to operate using our own personnel and our own management in the most important markets,” says Magnus Nilsson, Vitrolife’s CEO.

2 Nov 2009

Intervals between lung cancer diagnosis and treatment may attribute to health care discrepancies

Research published in the November 2009 issue of the Journal of Thoracic Oncology has found that intervals between lung cancer suspicion, diagnosis and treatment may be attributed to health care system discrepancies.

2 Nov 2009

Saft expands its portfolio with VL 10V Fe Super-Phosphate technology

Saft, the world specialist in the design and manufacture of high-tech batteries for industry, has expanded its range of lithium technologies with the VL 10V Fe Super-Phosphate(TM), the highest power lithium iron phosphate cell on the market. These large cells are designed for defense applications, such as U.S. Navy undersea operations, requiring very high power and safe operation.

2 Nov 2009

Local businesses team up to address youth homelessness

STANDUP FOR KIDS has been chosen by STAR OF THE NEIGHBORHOOD's "Featured Charity" program where thousands of local businesses are being asked to join forces for charity www.starkart.net/charity.

2 Nov 2009

Switching to new immunosuppressant drug may reduce skin cancer after kidney transplantation

Switching to a newer type of immunosuppressant drug may reduce the high rate of skin cancer after kidney transplantation, according to research being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA.

2 Nov 2009

CNS cancer survivors have greater neurocognitive dysfunction than survivors of other types of cancer

Brain tumors in childhood cast a long shadow on survivors. The first study of the lasting impact of these tumors -- the most common solid malignancies in childhood -- shows that survivors have ongoing cognitive problems.

2 Nov 2009

WCMC-Q's biomedical research program makes significant progress

The biomedical research program of Weill Cornell Medical College in Qatar has made significant progress in its dual goals of advancing basic science and building a sustainable research community in Qatar since it was launched less than a year and a half ago.

2 Nov 2009

Combination of inhibitor and antioxidants may help prevent diabetes complications

In diabetes patients, high blood glucose levels can end up killing certain cells in the eyes and kidneys, which is why diabetes is the leading cause of adult blindness and of kidney failure. Years ago, scientists identified one main route for this destruction—high glucose produces oxidative stress through the NF-kB molecular pathway—but success has been elusive for drugs targeting that pathway.

2 Nov 2009

Amgen publishes Phase 3 study results of Aranesp

Amgen today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes.

31 Oct 2009

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Schering-Plough Corp. announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.

31 Oct 2009

Stress-evoked changes can precipitate low mood and re-ignite drug-seeking behaviors

Stress-evoked changes in circuits that regulate serotonin in certain parts of the brain can precipitate a low mood and a relapse in cocaine-seeking, based on mouse studies published online this week in the Proceedings of the National Academy of Sciences.

31 Oct 2009

Johns Hopkins researchers find life in blood-starved retinas; shed light on vision loss

Like all tissues in the body, the eye needs a healthy blood supply to function properly. Poorly developed blood vessels can lead to visual impairment or even blindness. While many of the molecules involved in guiding the development of the intricate blood vessel architecture are known, only now are we learning how these molecules work and how they might affect sight.

31 Oct 2009

Immunotherapy, a new therapeutic area to destroy tumor cells

Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT).

31 Oct 2009

Cell News and Research

Study of combination therapy versus monotherapy for pulmonary arterial hypertension

Juvaris BioTherapeutics commences enrollment in its JVRS-100 influenza vaccine adjuvant study

VEGF from the retinal pigment epithelium to the choriocapillaris leads to degeneration of the CC, study finds

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

NOXXON Pharma commences human dosing in Spiegelmer NOX-A12 clinical trial

BMY and ZGen present Phase 1B results for PEG-Interferon lambda in HCV patients

InteRNA Technologies and Dana-Farber Cancer Institute team up for cancer research

Vitrolife takes over sales and marketing management of fertility media in UK and Ireland

Intervals between lung cancer diagnosis and treatment may attribute to health care discrepancies

Saft expands its portfolio with VL 10V Fe Super-Phosphate technology

Local businesses team up to address youth homelessness

Switching to new immunosuppressant drug may reduce skin cancer after kidney transplantation

CNS cancer survivors have greater neurocognitive dysfunction than survivors of other types of cancer

WCMC-Q's biomedical research program makes significant progress

Combination of inhibitor and antioxidants may help prevent diabetes complications

Amgen publishes Phase 3 study results of Aranesp

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Stress-evoked changes can precipitate low mood and re-ignite drug-seeking behaviors

Johns Hopkins researchers find life in blood-starved retinas; shed light on vision loss

Immunotherapy, a new therapeutic area to destroy tumor cells

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News